-
Mashup Score: 9SWOG Scores in Switzerland | SWOG - 15 day(s) ago
The world’s most important meeting on lymphoid neoplasms – the International Conference on Malignant Lymphoma (ICML), held biannually in Lugano, Switzerland – wraps up tomorrow morning. SWOG lymphoma research and lymphoma researchers have been well represented.
Source: www.swog.orgCategories: General Medicine NewsTweet
-
Mashup Score: 3S2302 Pragmatica-Lung Reports Out at ASCO | SWOG - 29 day(s) ago
S2302 results are in, indicating that the answer to that specific question is no, this investigational combination does not significantly improve overall survival (OS) for all patients. But as was clear from the content of two rapid oral abstract presentations at the ASCO 2025 Annual Meeting in Chicago earlier this week, Pragmatica-Lung remains a resounding success, as a proof of concept that incorporating streamlined and pragmatic design elements into large trials can help ensure rapid results that can be generalized to a broad and real-world population.
Source: www.swog.orgCategories: General Medicine NewsTweet-
Our @SWOGChair blog: S2302 Pragmatica-Lung Reports Out at #ASCO25 Although it didn't meet its primary endpoint, @SWOG's S2302 Pragmatica-Lung offers many lessons for future #clinicaltrials that are leaner, faster, more representative @ASCO @CancerResrch https://t.co/TwqKvePLl1 https://t.co/xRD0Z60XFM
-
-
Mashup Score: 16SWOG at ASCO, 2025 | SWOG - 1 month(s) ago
As part of the meeting’s opening session, Dr. Dawn Hershman, SWOG’s group co-chair-elect, will present the 2025 Karnofsky Science of Oncology Award Lecture (Saturday, May 31, 11 am CT, Hall B1 and livestreamed). The Karnofsky Award, which is ASCO’s highest scientific honor, recognizes oncologists who have made outstanding contributions in cancer research, diagnosis, and/or treatment.
Source: www.swog.orgCategories: General Medicine NewsTweet-
Our @SWOGChair's blog: SWOG at ASCO, 2025 Starting with @DrDawnHershman's Karnofsky Award Lecture in the opening session, the #ASCO25 Annual Meeting features some great @SWOG work in oncology research. https://t.co/R12B6BZQQX https://t.co/YycrxXujuy
-
-
Mashup Score: 9Community Site Engagement: Now In SWOG’s E Suite | SWOG - 2 month(s) ago
Most people treated for cancer in the U.S. are seen in community-based sites rather than in academic or NCI-designated cancer centers. The range often heard is that 80 to 85 percent of patients with cancer get their care at such sites. Similarly, many (by some counts, most) of the participants in both our treatment trials and our non-treatment trials are enrolled by community practice providers.
Source: www.swog.orgCategories: General Medicine NewsTweet-
Our @SWOGChair's blog: Community Site Engagement: Now In SWOG’s E Suite We've named @ROsarogiagbon executive officer for community site engagement, to help ⬆️ engagement w @SWOG trials at community practice sites, where 80-85% of those w cancer get treated https://t.co/jJkSjaAzws https://t.co/e4xjPIrXNt
-
-
Mashup Score: 11Next Week in San Francisco ... | SWOG - 2 month(s) ago
Events can’t get much more special than the 25th anniversary poster session for our Early Stage Investigators Training Course (ESITC). Six graduates of that course who are now leading SWOG trials will have posters on display late Wednesday through Friday, in the Grand Ballroom Foyer.
Source: www.swog.orgCategories: General Medicine NewsTweet-
Our @SWOGChair blog: Next Week in San Francisco ... We’ve reduced the # of days at spring group meeting, but we haven't reduced the range of exciting opportunities for education, networking, & prof development. I’m really looking forward to San Francisco! https://t.co/xjxGZiq1YW https://t.co/u6egbOkDZc
-
-
Mashup Score: 3An ASCO Hill Day in Interesting Times | SWOG - 3 month(s) ago
Overall, the mood of this Hill Day was cautious, but it was peppered with moments of optimism as well. ASCO had set three goals for our collective lobbying efforts:
Source: www.swog.orgCategories: General Medicine NewsTweet-
Our @SWOGChair blog: An @ASCO Hill Day in Interesting Times I was in DC last week to advocate for consistent+ funding for NIH, @theNCI, and ARPA-H in FY2026 and for other policies important to cancer research & to patients with cancer. #ASCOAdvocacySummit https://t.co/9ExFuOkAS1 https://t.co/dATSv28ycg
-
-
Mashup Score: 4TM Link of the Week: When Things Just Click | SWOG - 3 month(s) ago
In San Francisco, the consolidated plenary’s first segment (after my chair’s update) will be led by Dr. Lee Ellis, SWOG’s vice chair of TM, and will feature two speakers on TM work at SWOG. My first group meeting as SWOG chair, in spring 2013, featured a TM symposium led by Dr. Ellis, with Dr. James Rae, our executive officer for TM, as one of several speakers. And Drs. Ellis and Rae have been planning and providing cutting-edge TM content to SWOG members ever since, at Plenary 1 and beyond.
Source: www.swog.orgCategories: General Medicine NewsTweet-
Our @SWOGChair blog: TM Link of the Week: When Things Just Click Our TM leadership has brought many symposia, workshops, retreats, & plenaries to members. For 12 yrs now, they've also delivered a curated high-value TM article each week to busy clinicians. https://t.co/pJo0g21XEQ https://t.co/CTz7GNVaYa
-
-
Mashup Score: 1Meet the Advocate: Anne Marie Mercurio | SWOG - 4 month(s) ago
Anne Marie was diagnosed in the spring of 2006 with invasive lobular breast cancer. Eight rounds of chemo followed (as did a decade of endocrine therapy). That chemo took the toll it too often takes: in her words, “I knew my brain was scrambled [by it]”. She turned to a clinical trial of an intervention designed to help those suffering from chemo brain. She found, though, that the eligibility criteria were so restrictive that she “failed” the trial’s cognitive assessment for entry, scoring higher than the allowed cutoff.
Source: www.swog.orgCategories: General Medicine News, Oncologists1Tweet-
Our @SWOGChair's blog: Meet the Advocate: Anne Marie Mercurio Anne Marie Mercurio, co-chair of @SWOG’s patient advocate committee since October 2023, has been a social media pioneer in advocating for those with cancer. @chemobrainfog https://t.co/SUaBa1KYab
-
-
Mashup Score: 3Spring Group Meeting: Shorter, But Sweeter | SWOG - 5 month(s) ago
We have consolidated our group meeting schedule from four days to three, starting in spring of 2025. That meeting will run Thursday to Saturday, May 1st – 3rd, at the Hyatt Regency San Francisco. Registration opens SOON! Look for it on February 25th. Here’s a preview of the schedule (the meeting site will go live closer to registration day).
Source: www.swog.orgCategories: General Medicine News, Oncologists1Tweet-
Our @SWOGChair blog: Spring Group Meeting: Shorter, But Sweeter We've consolidated our group meeting schedule from 4 days to 3, starting in spring of 2025. We think this change will deliver substantial benefits, including a significant reduction in costs. https://t.co/SUjtBVyB1L https://t.co/1vQpDMKFgr
-
-
Mashup Score: 5Results of S1613: HER2 Inhibitors for HER2+ CRC | SWOG - 5 month(s) ago
The study compared treatment with dual HER2 inhibitors to a standard EGFR inhibitor-based treatment in patients with previously treated, HER2-positive disease. It found that the HER2 inhibitor treatment can provide similar benefit with less toxicity.
Source: www.swog.orgCategories: General Medicine News, Oncologists1Tweet-
Our @SWOGChair blog: Results of S1613: HER2 Inhibitors for HER2+ mCRC Our S1613 trial results are out in @JCO_ASCO. Particularly intriguing -- relative benefit of dual HER2 inhibitors vs EGFR inhibitor tx seems tied to the level of HER2 amplification. https://t.co/BVMv2GifSn https://t.co/Brs9eLHIGU
-
Our @SWOGChair blog: SWOG Scores in Switzerland The world’s most important meeting on lymphoid neoplasms – the International Conf. on Malignant Lymphoma (#18ICML) – ends tomorrow in Lugano. @SWOG lymphoma research & researchers have been well represented. https://t.co/czWajHDWq9 https://t.co/G4ucRxPL9c